[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ms-multiple-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ms-multiple-sclerosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,65,105,130,156,182,214,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100576240","phase-2-psilocybin-therapy-for-psychological-distress-in-palliative-patients-100576240",false,"NCT06782724","Psilocybin Therapy for Psychological Distress in Palliative Patients","The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.","PsyPal","Inclusion Criteria:\n\n1. Patient has to be diagnosed with one of the following four conditions, defined as:\n\n   COPD i) Diagnosis by medical specialist ii) Postbronchodilator FEV1\u002FFVC \\\u003C 0,7 and FEV1 \\\u003C80% pred iii) ≥ 40 years old iv) ≥ 10 years smoking\n\n   ALS i) ALS according to Goldcoast criteria (Shefner et al, Clin Neurophysiol, 2020) ii) ALS-FRS-R subscores of minimum 1 in item 2, 3 and 8, subscore of minimum 2 in item 1, 4 and 10 and a subscore of minimum 3 in item 11 and 12\n\n   MS i) Fulfilled diagnostic revised McDonald criteria for MS from 2017 (Thompson et al., 2018) ii) EDSS ≥ 1,0\n\n   APD i) Advanced to Late-Stage Parkinson's Disease - patients with a diagnosis of Parkinson's Disease per the MDS clinical diagnosis criteria with evidence of motor and non-motor fluctuations ii) Diseases in the spectrum of Progressive supranuclear palsy (PSP), fulfilling possible and probable criteria, according to the MDS diagnostic criteria iii) Clinically Established and Clinically Probable Multiple System Atrophy (MSA) according to the MDS diagnostic criteria\n2. Patient meets ICD-10 criteria for major depressive disorder documented through the com-pletion of the mood section of the Mini International Neuropsychiatric Interview by a screen-ing psychologist or physician.\n3. Patient has a MADRS score of \\> 19.\n4. Patient should have a life expectancy of at least 6 months (assessed by study physician).\n5. Patient is at least 18 years of age.\n6. Patient has an identified caregiver\u002Fsupport person. See specific conditions for Czechia in Appendix 5.\n7. Patient is able to read and understand the informed consent and all scales used in a local language. For those with ALS, MS, or APD, competency is ensured via neurologist assessment, cognitive screening, caregiver support during screening and interactive approaches where the screening clinician ask the patient to explain their understanding of consent elements, re-explaining potentially misunderstood information.\n8. Patient is able to and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations.\n9. Patient is able to ingest capsules.\n\nExclusion Criteria:\n\n1. Patient has used a psychedelic substance in the past 6 months (e.g., psilocybin, LSD, 5-MeO-DMT, DMT, ayahuasca or mescaline).\n2. Patient is in active treatments for other psychiatric disorders, judged by the screening clinician to be a more significant clinical problem than depression \u002F distress.\n3. Patient meets ICD-10 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features (except substance\u002Fmedication-induced or due to another medical condition) or bipolar I\u002FII disorder.\n4. Patients with any lifetime diagnosis of schizophrenia spectrum or other psychotic disorders.\n5. Patient has a first-degree relative with schizophrenia spectrum, bipolar I disorder or other psychotic disorders (expect substance\u002Fmedication-induced or due to another medical condition).\n6. Patients with a pre-existing psychiatric condition judged to be incompatible with safe exposure to psilocybin therapy.\n7. Significant suicide risk as defined by (1) suicidal ideation with intent to act (defined as ≥ 5 on MADRS item 10), (2) suicidal attempts within the past year, or (3) clinical assessment of significant suicidal risk during patient interview.\n8. Patient meets ICD-10 criteria for active\u002Fcurrent alcohol or drug use disorder.\n9. Patient has ongoing treatment with antipsychotic drugs. Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug at the time of baseline (see Appendix 1a for Prohibited medications).\n10. Patient is unwilling or unable to pause formal psychotherapy (days 0-42).\n11. Patient has neurological conditions (e.g., intracranial tumour, epilepsy, brain injuries, or other neurological disorders) expected by the PIs to conflict with the treatment \u002F study protocol.\n12. Disease-specific exclusion criteria:\n\n    COPD: Unresolved exacerbation or pulmonary infection within last 4 weeks. ALS: Significant cognitive deficits (MoCa, see below). MS: Significant cognitive deficits (MoCa, see below), epilepsy or radiologically isolated syndrome.\n\n    APD: Dementia (MoCa, see below), or Schwab and England ADL scale with scores \\> 80% in the best functional state.\n13. Cardiovascular conditions: recent stroke (\\\u003C 1 year from signing of ICF), recent myocardial infarction (\\\u003C 1 year from signing of ICF), uncontrolled hypertension (blood pressure \\> 140\u002F90 mmHg), clinically significant arrhythmia within 1 year of signing the ICF, or QTc prolongation exceeding 450ms (males) \u002F 470ms (females).\n14. Patient has moderate to severe hepatic impairment (Child-Pugh score ≥ 7).\n15. Patient has insulin-dependent diabetes or who are taking oral hypoglycaemic agents and have a current risk of hypoglycaemia that would require medical intervention.\n16. Patient has any physical or psychological symptoms, medications, blood test results or clinically significant findings at Screening or Baseline (based on the clinical judgement of clinical\u002Fmedical study personnel) that would make a patient unsuitable for the study.\n17. Patient has an allergy or intolerance to any of the materials contained in either drug product.\n18. Cognitive and Neuropsychological assessment: Patients will be excluded if they score below mean minus 1.5 Standard Deviation according to normative age and scholarity adjusted data on the Montreal Cognitive Assessment (MoCA) assessment.\n19. Recent (2 weeks) change or planned change in antidepressant medication during the intervention.\n20. Women who are pregnant, intend to become pregnant during the study or who are currently nursing, or are unwilling to use Highly Effective Contraceptive Methods","ALL","18 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are:\n\n* Can psilocybin therapy safely reduce depressive symptoms compared to low-dose control?\n* Will the therapeutic effects be rapid and sustained over a 6-month period?\n\nResearchers will compare patients receiving two escalating doses of psilocybin (15mg followed by 25mg) against those receiving two low doses (1mg) to see if the higher doses lead to greater improvements in depression, anxiety, demoralization, and quality of life.\n\nParticipants will:\n\n* Attend three preparation sessions with psychotherapists (1-2 hours each)\n* Undergo two supervised psilocybin dosing sessions (6-8 hours each)\n* Complete five integration therapy sessions following the dosing sessions\n* Participate in follow-up assessments at 6 weeks, 3 months, and 6 months\n* Have access to a digital care platform and peer support groups during the 6-month follow-up period\n* Optional: Control group participants may receive one high-dose psilocybin session (25mg) after the initial study period",[27,28,29,30,31],"COPD (Chronic Obstructive Pulmonary Disease)","ALS (Amyotrophic Lateral Sclerosis)","MS (Multiple Sclerosis)","Major Depressive Disorder (MDD)","Atypical Parkinson Disease",[33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"psilocybin","therapy","palliative","care","palliative care","end-of-life distress","depression","psychological distress","psypal","copd","als","ms","apd","chronic obstructive pulmonary disorder","amyotrophic lateral sclerosis","multiple sclerosis","major depressive disorder","atypical parkinson disease","existential distress","RECRUITING","2026-05-04",{"date":55,"type":56},"2026-05-08","ACTUAL",{"date":58,"type":56},"2025-07-01",{"date":60,"type":21},"2028-01-01",{"name":62,"class":63},"University Medical Center Groningen","OTHER",4,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":86,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100608487","at-home-use-of-stimulation-suits-for-managing-ms-symptoms-100608487","NCT07202195","At Home Use of Stimulation Suits for Managing MS Symptoms","Home-Based Neuromodulation Suits for Reducing Spasticity and Ataxia in Multiple Sclerosis: A Multi-center RCT","HANDS-MS","Inclusion Criteria:\n\n* Eligible participants must have ataxia or spasticity alongside impairments in upper or lower extremity physical function. MAS score ≥ 1 will be used as an inclusion criterion to determine the presence of spasticity. SARA score ≥ 4 will be used as an inclusion criterion to determine the presence of ataxia. Note: one of the two criteria (MAS score or SARA score) must be fulfilled for a pwMS to be eligible.\n* The patient must have the cognitive abilities to understand instructions and to be able to complete the questionnaires adequately\n* Diagnosis of multiple sclerosis.\n\nExclusion Criteria:\n\n* Implanted devices (like pacemaker, Baclofen pump, neurostimulator, defibrillator, shunts, ECG equipment, electronic life support, high frequency operation equipment )\n* Change in disease modifying treatment within the last 3 months\n* Use of Botuline Toxine A within the last 3months\n* Recent relapse within the last 3 months\n* Acute musculoskeletal problems that hinder the test performance,\n* Pregnancy\n* Sizes bigger than 3XL (triple eXtra Large)\n* Skin eruptions and\u002For skin areas in the stimulation zone that are swollen, infected or inflamed.",{"count":74,"type":21},70,[76],"NA","This study is being carried out at Multiple Sclerosis (MS) centers to evaluate whether a full-body stimulation suit at home can help people with Multiple Sclerosis (pwMS) reduce symptoms like spasticity (muscle stiffness) and ataxia (poor coordination), and improve daily functioning.\n\nCan pwMS who experience spasticity or ataxia benefit from using a stimulation suit for 6 weeks?\n\nResearchers will compare two groups: an intervention group (who will use the suit) and a control group (who will not use the suit).\n\nParticipants in the intervention group will:\n\n* Wear the suit for 6 weeks in total every day or every other day (1 week during their MS center admission and 5 weeks at home).\n* Receive their usual care in addition to wearing the suit.\n* Undergo clinical tests at the MS center after 1 week and 6 weeks of stimulation.\n\nParticipants in the control group will:\n\n* Receive their usual care.\n* Undergo clincial tests at the same time points as the other group.",[79,29,80,81,82,83,84,85],"Multiple Sclerosis","Spasticity With Multiple Sclerosis","Ataxia - Other","Ataxia, Cerebellar","Ataxia, Motor","Spasticity","Home Based Care",[87,88,48,89,90,91,92,93,94],"ataxia","spasticity","MS","neuromodulation suit","stimulation suit","exopluse molli suit","home-based rehabilitation","symptom management","2026-02-04",{"date":97,"type":56},"2026-02-06",{"date":99,"type":21},"2026-03",{"date":101,"type":21},"2027-09",{"name":103,"class":63},"Daphne Kos",2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":115,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100616388","multiple-sclerosis-versus-neuromyelitis-optica-spectrum-disorder-100616388","NCT07304960","Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder","Comparative Study Between Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder Patients in Assiut Hospitals Clinical and Laboratory Study","Inclusion Criteria:1- Both sex 2- Aged between 18 and 50 years. All included patients were in a clinically stable phase and had not experienced a relapse within at least three months before blood sampling. 3- All patients diagnosed as MS patients either naive or on disease modifying therapies according to The new diagnostic criteria MacDonalds 2024 4- DMT-naïve NMOSD patients: Diagnosed with MS based on the 2017 McDonald Criteria (Thompson et al., 2018)\n\n5- An informed consent will be obtained from all the patients; the study will be approved by ethical committee in faculty of Medicine Assiut University\n\n\\-\n\n1\\_ Presence of other disorder that mimic MS or NMOSD 3\\_ Patients failed to commit to the follow up visits and regular MRI scans 4\\_ Patients refused to sign the written informed consent\n\nExclusion Criteria:\n\n* 1\\_ Presence of other disorder that mimic MS or NMOSD 3\\_ Patients failed to commit to the follow up visits and regular MRI scans 4\\_ Patients refused to sign the written informed consent","50 Years",{"count":114,"type":21},100,"6 Months","OBSERVATIONAL","The aim of this work is to do a detailed comparison between multiple sclerosis and Neuromyelitis Optica Spectrum Disorder due to delicate similarities between both diseases and wide rang of management and follow up of the patients",[29,119],"NMO Spectrum Disorder (NMOSD)","NOT_YET_RECRUITING","2025-12-12",{"date":123,"type":56},"2025-12-26",{"date":125,"type":21},"2026-01-01",{"date":127,"type":21},"2030-12-22",{"name":129,"class":63},"Assiut University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100610056","selfie-videos-a-novel-patient-centered-comprehensive-approach-to-measuring-function-in-ms-100610056","NCT07222618","\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","Inclusion Criteria:\n\n* Any patient with MS who is above the age of 18 yrs. Participants who are unable to consent for themselves must have a surrogate decision maker or LAR.\n* Age \\> 18 yrs, EDSS - \\\u003C6.5, own a video recording device (smartphone, tablet, camera etc).\n\nExclusion Criteria:\n\n* Patient unwilling to participate in the study. Participants unable to consent for themselves who do not have a surrogate decision maker or LAR.",{"count":137,"type":21},300,"The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired \"selfie\" videos in people with multiple sclerosis. The investigators aim to prove the feasibility and validity of monitoring walking changes remotely through a truly patient-centered, low-burden, low-cost approach. The main question this study aims to answer is: do remotely collected walking and speech videos from a mobile phone match the information investigators can gather from an in person visit?\n\nParticipants will collect 5 \"selfie\" videos at baseline, 3 months, 6 months and 12 months (about 15 minutes every 3 months). They will also come in person at baseline, 6 months, and 12 months for in person data collection (about 1 hour per in person visit).",[79,140,141,29,89,142],"Multiple Sclerosis (MS) - Relapsing-remitting","Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis (MS) Secondary Progressive",[48,89,144,145],"digital tool","UCSF","2025-10-29",{"date":148,"type":56},"2025-10-31",{"date":150,"type":56},"2025-10-01",{"date":152,"type":21},"2028-10-01",{"name":154,"class":63},"University of California, San Francisco",1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":155},"100599698","assessment-of-transcranial-alternating-current-stimulations-clinical-efficacy-in-treating-cognitive-impairment-of-idiopathic-inflammatory-demyelinating-diseases-100599698","NCT07087873","Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases","TACS-CI-IIDDs","Inclusion Criteria:\n\n* Age: 18-60 years old.\n* Diagnosis: Patients with neuromyelitis optica spectrum disease, multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system that meet the diagnostic criteria.\n* Medications have been stable for at least three months.\n\nExclusion Criteria:\n\n* Recurrence has been recorded in the past 3 months.\n* Have a pacemaker or other metal implant in the body.\n* Impaired skin integrity at the site of electrode placement.\n* Previous organic brain disease such as epilepsy, hydrocephalus, central nervous system tumors, brain injury, or intracranial infection.\n* Combined with severe or unstable organic diseases, such as heart, liver and kidney and other organ dysfunction.\n* Pregnant or lactating women, those who are planning to become pregnant in the near future.\n* Patient compliance is poor.\n* In the opinion of the investigator, there is a situation that is not suitable to participate in this study.","60 Years",{"count":165,"type":21},128,[76],"This study aims to explore the imaging and electrophysiological characteristics of idiopathic inflammatory demyelinating diseases (IIDDs), and their correlation with clinical manifestations. It also evaluates the effectiveness of transcranial electrical stimulation in alleviating clinical symptoms of IIDDs patients, and analyzes the key factors affecting the treatment efficacy. By uncovering the overall and individual characteristics of IIDDs, this study seeks to enhance therapeutic outcomes through personalized neuromodulation programs. The findings will provide a basis for applying non-invasive brain stimulation (NIBS) in IIDDs treatment and offer new ideas for future personalized medicine approaches.",[169,29,170,171,172],"Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System","NMOSD","Acute Disseminated Encephalomyelitis","Transcranial Alternating Current Stimulation","2025-07-24",{"date":175,"type":56},"2025-07-28",{"date":177,"type":56},"2025-05-30",{"date":179,"type":21},"2027-10-31",{"name":181,"class":63},"Xuanwu Hospital, Beijing",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":17,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":194,"conditions":195,"keywords":201,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":155},"100592899","phase-1-exploring-the-utility-of-18f3f4ap-for-demyelination-imaging-100592899","NCT06999434","Exploring the Utility of [18F]3F4AP for Demyelination Imaging","Inclusion:\n\n1. Male and Female subjects must be ≥18 and \\\u003C90 years of age;\n2. Able to understand and provide informed consent prior to study procedures\n3. Must be in good health\n\nExclusion:\n\n1. Less than 18 years of age;\n2. Pregnant or breastfeeding;\n3. Any significant systemic illness or unstable medical condition;\n4. Pre-existing medical conditions or claustrophobic reactions;\n5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);\n6. History of a bleeding disorder or are currently taking anticoagulants.",true,"90 Years",{"count":191,"type":21},105,[193],"PHASE1","The overall objective is to obtain an assessment of the pharmacokinetics of \\[18F\\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).",[196,197,198,29,199,200],"Demyelinating Disorders","MCI","Alzheimer's Disease (AD)","SCI - Spinal Cord Injury","Spinal Radiculopathy",[202,196,89,203,204],"3F4AP","SCI","AD","2025-05-22",{"date":207,"type":56},"2025-05-31",{"date":209,"type":56},"2025-05-05",{"date":211,"type":21},"2030-05-05",{"name":213,"class":63},"Yale University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":155},"100581405","dubousset-functional-test-an-investigation-of-its-validity-and-reliability-in-individuals-with-multiple-sclerosis-100581405","NCT06849882","Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis","Inclusion Criteria:\n\n* Being diagnosed with MS,\n* Over 18 years of age and under 65 years of age,\n* To be able to balance independently in standing position.\n* EDSS score of 3.5 and below\n* At the appropriate cognitive level to adapt to the tests to be performed in the study,\n* Completed primary school level,\n\nExclusion Criteria:\n\n* Relapse within the last 30 days,\n* Loss of balance or gait disturbance affected by a condition other than MS,\n* Being pregnant for female individuals,\n* An attack of optic neuritis in the last month\n* Individuals who are unable to perform the task due to sensory, cognitive or other problems will be excluded.","65 Years",{"count":222,"type":21},33,"Multiple sclerosis (MS) is an autoimmune disease characterized by neuroinflammation and neurodegeneration in the central nervous system. The disease affects the white matter, cortex and deep gray matter of the central nervous system and is characterized by inflammatory-demyelinating lesions and neuronal\u002Faxonal degeneration. Demyelination associated with these lesions and the accompanying axonal degeneration are responsible for neurological disability in MS. There are many scales and mobility and functional performance tests in the literature to assess balance, such as the Sit Reach Test, Timed Up and Go (TUG) test, Tinetti Performance Oriented Mobility Assessment (POMA), Berg Balance Scale (BBS) (5) and Balance Evaluation System Test (BESTest). The most appropriate balance assessment scales for individuals with MS are those that assess static and dynamic sitting balance while standing and dynamic balance only. Since balance in individuals with MS is a dynamic process that changes gradually, new measurement methods that can record these changes and determine the appropriate treatment for these variables are needed.\n\nThe Dubousset Functional Test (DFT) was developed by Dr. Jean Dubousset as a four-component practical assessment to evaluate the physical function and balance capacity of individuals with spinal deformity. The DFT consists of four components: getting up from an armless chair and walking 5 meters forward and backward, ascending and descending steps, transition from standing to sitting position, and gait assessment with a dual task test (counting backwards from 50). The difference of this test from the others is that it evaluates the spinopelvic muscle groups that are directly related to functionality, maintains the global trunk alignment of the individual and provides objective results about functional performance and balance. In addition, unlike other functional performance tests, the DFT assesses the neurophysiological effects of the process that requires individuals to perform two tasks at the same time by measuring their coordination, balance, attention and thinking skills during functioning through a dual task component. The validity and reliability of this test has been previously investigated in low back pain, stroke, parkinson's disease, elderly individuals and hemiplegia. In this study, it was aimed to examine the validity and reliability of the Dubousset functional test in individuals with multiple sclerosis.",[29],[79,226,227,228],"Dubousset Functional Test","Validity","Reliability","2025-02-27",{"date":231,"type":56},"2025-03-03",{"date":233,"type":56},"2025-02-10",{"date":235,"type":21},"2025-05",{"name":237,"class":63},"Inonu University",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100575336","frequency-of-gastrointestinal-and-hepatic-manifestations-among-patients-with-multiple-sclerosis-a-clinical-hospital-based-study-100575336","NCT06770959","Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study","Inclusion Criteria:\n\n* 1- both sex 2- All patients diagnosed MS ( in recovery on DMT) according to the 2017-McDonalds criteria.\n\n  3- Pt with MS suffer from git and hepatic symptoms not explained by known cause as Hepatitis virus،metabolic disorders as Wilson . hemochromatosis,etc Drug induced , Alcohol , Git symptoms as dysphagia, vomiting,reflux\n\n  4- An informed consent will be obtained from all the patients, the study will be approved by ethical committee in faculty of Medicine Assiut University\n\nExclusion Criteria :1-patients already diagnosed with other GIT disorders before diagnosis of MS\n\n2\\_ Presence of other disorder or on medications that may affect the neurological or GIT disorders.\n\n3\\_ Patients failed to commit to the follow up visits and regular MRI scans 4\\_ Patients refused to sign the written informed consent Patients who will meet the inclusion and exclusion criteria will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments. Baseline MRI scans will be obtained at the first visit\n\n\\-",{"count":245,"type":21},80,"The aim of this work is to identify different pattern of Gastrointestinal and Hepatic symptoms and its Frequency among patients with Multiple Sclerosis",[29],"2025-01-07",{"date":250,"type":56},"2025-01-13",{"date":252,"type":21},"2025-01",{"date":254,"type":21},"2026-12",{"name":129,"class":63}]